NCT03195192View on ClinicalTrials.gov

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Metastatic Breast Cancer

Interventions

OTHER

biomarker study

This is a biomarker study

Trial Locations (8)

19104

Abramson Cancer Center Perelman Center for Advanced Medicine, Philadelphia

19107

Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

33136

UHealth/Sylvester Comprehensive Cancer Center, Miami

90048

Cedars-Sinai Medical Center, Los Angeles

98109

University of Washington, Seattle

35294-0113

University of Alabama at Birmingham, Birmingham

02905

Women & Infants Hospital of Rhode Island, Providence

All Listed Sponsors

collaborator

Translational Drug Development

OTHER

lead

Side-Out Foundation

OTHER

NCT03195192 - Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter